CLDX Q4 2020 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+326.7% YoY

Gross Profit

-$7M-175.4% margin

Operating Income

-$25M-654.7% margin

Net Income

-$22M-578.6% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+466.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$236M

Total Liabilities

$26M

Stockholders' Equity

$209M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$887,000	+326.7%
Gross Profit	-$7M	-$9M	+29.8%
Operating Income	-$25M	-$13M	-90.8%
Net Income	-$22M	-$10M	-109.6%

Revenue Segments

Grant

$4M100%

Service

$4,0000%